UCB, a global biopharmaceutical company, is presenting its research on generalized myasthenia gravis (gMG) at two annual meetings. It will present additional results from the MycarinG and RAISE studies on its drugs rozanolixizumab-noli and zilucoplan. Both drugs, recently approved by the US FDA and Japanese authorities, are under review by the European Medicines Agency for the treatment of adults with gMG. UCB is also assessing the drugs in pediatric patients with gMG.
News – Masimo reports cyber incident affecting production sites – teiss
Masimo has reported a cyber incident that has impacted its production sites. The company is currently assessing the situation to understand the extent of the
